JP2010514702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514702A5 JP2010514702A5 JP2009543271A JP2009543271A JP2010514702A5 JP 2010514702 A5 JP2010514702 A5 JP 2010514702A5 JP 2009543271 A JP2009543271 A JP 2009543271A JP 2009543271 A JP2009543271 A JP 2009543271A JP 2010514702 A5 JP2010514702 A5 JP 2010514702A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- effective amount
- therapeutically effective
- dosage form
- pharmaceutical dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 14
- 239000002552 dosage form Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 5
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 4
- 239000003613 bile acid Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 229940126409 proton pump inhibitor Drugs 0.000 claims 4
- 239000000612 proton pump inhibitor Substances 0.000 claims 4
- 239000002516 radical scavenger Substances 0.000 claims 4
- 239000003185 4 aminobutyric acid B receptor stimulating agent Substances 0.000 claims 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- VTAKZNRDSPNOAU-UHFFFAOYSA-M 2-(chloromethyl)oxirane;hydron;prop-2-en-1-amine;n-prop-2-enyldecan-1-amine;trimethyl-[6-(prop-2-enylamino)hexyl]azanium;dichloride Chemical compound Cl.[Cl-].NCC=C.ClCC1CO1.CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C VTAKZNRDSPNOAU-UHFFFAOYSA-M 0.000 claims 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 2
- 208000023514 Barrett esophagus Diseases 0.000 claims 2
- 208000023665 Barrett oesophagus Diseases 0.000 claims 2
- 229920002905 Colesevelam Polymers 0.000 claims 2
- 206010063655 Erosive oesophagitis Diseases 0.000 claims 2
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 2
- 206010030216 Oesophagitis Diseases 0.000 claims 2
- 208000008469 Peptic Ulcer Diseases 0.000 claims 2
- 201000007100 Pharyngitis Diseases 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 229940069428 antacid Drugs 0.000 claims 2
- 239000003159 antacid agent Substances 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 210000000981 epithelium Anatomy 0.000 claims 2
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 2
- 208000006881 esophagitis Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 208000024798 heartburn Diseases 0.000 claims 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960003174 lansoprazole Drugs 0.000 claims 2
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims 2
- 230000005980 lung dysfunction Effects 0.000 claims 2
- 208000011906 peptic ulcer disease Diseases 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims 1
- PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 claims 1
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 claims 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims 1
- KPYSYYIEGFHWSV-QMMMGPOBSA-N Arbaclofen Chemical group OC(=O)C[C@@H](CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-QMMMGPOBSA-N 0.000 claims 1
- 101710110426 Aspartyl protease inhibitor Proteins 0.000 claims 1
- 229920001268 Cholestyramine Polymers 0.000 claims 1
- 229920002911 Colestipol Polymers 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 claims 1
- 102000057297 Pepsin A Human genes 0.000 claims 1
- 108090000284 Pepsin A Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000003973 alkyl amines Chemical class 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 230000001458 anti-acid effect Effects 0.000 claims 1
- 239000003696 aspartic proteinase inhibitor Substances 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 1
- 239000000920 calcium hydroxide Substances 0.000 claims 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 claims 1
- 229960001380 cimetidine Drugs 0.000 claims 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical group N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims 1
- 229960001152 colesevelam Drugs 0.000 claims 1
- 229960000674 colesevelam hydrochloride Drugs 0.000 claims 1
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims 1
- 229960002604 colestipol Drugs 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- -1 dontoprazole Chemical compound 0.000 claims 1
- 229960004770 esomeprazole Drugs 0.000 claims 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 claims 1
- 229960001596 famotidine Drugs 0.000 claims 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 229950007395 leminoprazole Drugs 0.000 claims 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims 1
- 239000001095 magnesium carbonate Substances 0.000 claims 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims 1
- 229960004872 nizatidine Drugs 0.000 claims 1
- 229960000381 omeprazole Drugs 0.000 claims 1
- 229960005019 pantoprazole Drugs 0.000 claims 1
- 229940111202 pepsin Drugs 0.000 claims 1
- 229950000964 pepstatin Drugs 0.000 claims 1
- 108010091212 pepstatin Proteins 0.000 claims 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 claims 1
- 229960004157 rabeprazole Drugs 0.000 claims 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 claims 1
- ZNSIZMQNQCNRBW-UHFFFAOYSA-N sevelamer Chemical compound NCC=C.ClCC1CO1 ZNSIZMQNQCNRBW-UHFFFAOYSA-N 0.000 claims 1
- 229960003693 sevelamer Drugs 0.000 claims 1
- 229950008375 tenatoprazole Drugs 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 claims 1
- 229960001661 ursodiol Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87149906P | 2006-12-22 | 2006-12-22 | |
| PCT/US2007/088624 WO2008080092A2 (en) | 2006-12-22 | 2007-12-21 | Compositions comprising bile acid sequestrants for treating esophageal disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015016788A Division JP6141891B2 (ja) | 2006-12-22 | 2015-01-30 | 食道障害の治療方法および治療用組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010514702A JP2010514702A (ja) | 2010-05-06 |
| JP2010514702A5 true JP2010514702A5 (https=) | 2011-02-10 |
Family
ID=39277294
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009543271A Pending JP2010514702A (ja) | 2006-12-22 | 2007-12-21 | 食道障害の治療方法および治療用組成物 |
| JP2015016788A Expired - Fee Related JP6141891B2 (ja) | 2006-12-22 | 2015-01-30 | 食道障害の治療方法および治療用組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015016788A Expired - Fee Related JP6141891B2 (ja) | 2006-12-22 | 2015-01-30 | 食道障害の治療方法および治療用組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9205094B2 (https=) |
| EP (4) | EP2124884B1 (https=) |
| JP (2) | JP2010514702A (https=) |
| AU (1) | AU2007336731B2 (https=) |
| CA (1) | CA2673665C (https=) |
| CY (1) | CY1122009T1 (https=) |
| DK (1) | DK2124884T3 (https=) |
| ES (1) | ES2739542T3 (https=) |
| HU (1) | HUE046465T2 (https=) |
| IL (1) | IL199477A (https=) |
| LT (1) | LT2124884T (https=) |
| NZ (2) | NZ578204A (https=) |
| PL (1) | PL2124884T3 (https=) |
| PT (1) | PT2124884T (https=) |
| RU (3) | RU2491075C2 (https=) |
| SI (1) | SI2124884T1 (https=) |
| TR (1) | TR201910825T4 (https=) |
| WO (1) | WO2008080092A2 (https=) |
| ZA (1) | ZA200904573B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2124884B1 (en) | 2006-12-22 | 2019-07-10 | Ironwood Pharmaceuticals, Inc. | Compositions comprising bile acid sequestrants for treating esophageal disorders |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| TWI605837B (zh) * | 2011-01-27 | 2017-11-21 | Kowa Co Ltd | Pharmaceutical composition containing water-insoluble drug and pharmaceutical preparation |
| ITRM20120041A1 (it) * | 2012-02-08 | 2013-08-09 | Dicofarm Spa | "prodotto a base di glucomannano e chitosano utile per il trattamento del reflusso gastroesofageo" |
| CA2898362C (en) * | 2013-01-15 | 2020-09-01 | Ironwood Pharmaceuticals, Inc. | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |
| ES2908142T3 (es) | 2014-06-13 | 2022-04-27 | United Therapeutics Corp | Formulaciones de treprostinil |
| TWI705814B (zh) * | 2014-06-20 | 2020-10-01 | 美商梅琳塔有限責任公司 | 醫藥組成物及其用途 |
| SG11201903911UA (en) * | 2016-11-02 | 2019-05-30 | Novartis Ag | Combinations of fgfr4 inhibitors and bile acid sequestrants |
| RU2667651C1 (ru) * | 2017-12-26 | 2018-09-21 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения эрозивной формы гастроэзофагеальной рефлюксной болезни у пациентов, получающих химиотерапию |
| WO2020077186A1 (en) * | 2018-10-12 | 2020-04-16 | Icahn School Of Medicine At Mount Sinai | Azd3355 (lesogaberan) for treatment and prevention of nonalcoholic steatohepatitis (nash), liver fibrosis, and other liver conditions |
| EP4135740A4 (en) * | 2020-04-16 | 2024-05-22 | The Medical College of Wisconsin, Inc. | AEROSOL FORMULATIONS OF HIV PROTEASE INHIBITORS FOR THE TREATMENT OF RESPIRATORY REFLUX |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3624209A (en) * | 1966-12-28 | 1971-11-30 | Bristol Myers Co | Composition for treatment of gastro-intestinal disorders |
| US3692895A (en) | 1970-09-08 | 1972-09-19 | Norman A Nelson | Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria |
| SE416649B (sv) | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
| DE2704425C2 (de) * | 1977-02-03 | 1982-10-07 | Interx Research Corp., 66044 Lawrence, Kan. | Verwendung von Styrol-Divinylbenzol-Copolymer-Anionenaustauscherharzen bei der Bekämpfung von Magengeschwüren |
| GB1566609A (en) * | 1977-03-10 | 1980-05-08 | Reckitt & Colmann Prod Ltd | Pharmaceutical compositions containing cholestyramine and alginic acid |
| SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| JPS5692217A (en) | 1979-12-26 | 1981-07-25 | Kowa Co | Easily absorbable enzyme preparation |
| US4359465A (en) | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
| US4472409A (en) | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
| AU545463B2 (en) | 1982-06-25 | 1985-07-18 | Kowa Co. Ltd. | Benzoyl piperacine esters |
| SE8300736D0 (sv) | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
| SE8301182D0 (sv) | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| JPS59222484A (ja) | 1983-06-02 | 1984-12-14 | Kowa Co | テトラヒドロナフチルカルボン酸フエニルエステル誘導体 |
| JPS608225A (ja) | 1983-06-29 | 1985-01-17 | Kowa Co | 腸管吸収医薬組成物 |
| IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
| US4735804A (en) | 1985-05-10 | 1988-04-05 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4738975A (en) | 1985-07-02 | 1988-04-19 | Takeda Chemical Industries, Ltd. | Pyridine derivatives, and use as anti-ulcer agents |
| CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| FI90544C (fi) | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
| US4851232A (en) | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
| FI96860C (fi) | 1987-06-17 | 1996-09-10 | Eisai Co Ltd | Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| JP2916205B2 (ja) | 1990-04-28 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ペプチド |
| JP2916206B2 (ja) | 1990-04-28 | 1999-07-05 | 帝國製薬株式会社 | 生理活性ペプチド |
| DK223790D0 (da) | 1990-09-18 | 1990-09-18 | Novo Nordisk As | Proteaseholdig detergentkomposition |
| US5312824A (en) | 1990-10-17 | 1994-05-17 | Takeda Chemical Industries, Ltd. | Certain 2-[(4-difluoromethoxy-2-pyridyl)-methylthio or methylsulfinyl-5-benzimidazoles useful for treating peptic ulcers |
| US5167483A (en) | 1990-12-24 | 1992-12-01 | Gardiner Samuel W | Method for utilizing angular momentum in energy conversion devices and an apparatus therefore |
| IT1245891B (it) * | 1991-04-12 | 1994-10-25 | Alfa Wassermann Spa | Formulazioni farmaceutiche a rilascio controllato per uso orale gastroresistenti contenenti acidi biliari e loro sali. |
| YU48263B (sh) | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| US5877192A (en) | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
| US5703188A (en) | 1993-06-02 | 1997-12-30 | Geltex Pharmaceuticals, Inc. | Process for removing bile salts from a patient and compositions therefor |
| US5670163A (en) | 1994-06-20 | 1997-09-23 | Kv Pharmaceuticals Company | Long acting GI and esophageal protectant |
| CH689139A5 (de) | 1995-04-03 | 1998-10-30 | Cerbios Pharma Sa | Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung. |
| DE19534996A1 (de) | 1995-09-21 | 1997-03-27 | Bosch Gmbh Robert | Verfahren zur Verbrennungsaussetzererkennung durch Auswertung von Drehzahlschwankungen |
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| US6423754B1 (en) | 1997-06-18 | 2002-07-23 | Geltex Pharmaceuticals, Inc. | Method for treating hypercholesterolemia with polyallylamine polymers |
| JP2001527023A (ja) | 1997-08-11 | 2001-12-25 | アルザ・コーポレーション | 胃で保持するのに適合した長期放出性活性剤剤形 |
| US20040062802A1 (en) | 1998-04-02 | 2004-04-01 | Hermelin Victor M. | Maximizing effectiveness of substances used to improve health and well being |
| DE19850309A1 (de) | 1998-10-30 | 2000-05-04 | Lohmann Therapie Syst Lts | Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer |
| IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| US6881420B2 (en) | 2000-06-23 | 2005-04-19 | Teva Pharmaceutical Industries Ltd. | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation |
| US6638498B2 (en) | 2000-06-30 | 2003-10-28 | Semorex Inc. | Molecularly imprinted polymers for the treatment and diagnosis of medical conditions |
| EP1307263B1 (en) | 2000-07-28 | 2005-04-20 | F. Hoffmann-La Roche Ag | New use of lipase inhibitors |
| RU2241462C2 (ru) * | 2000-07-28 | 2004-12-10 | Ф. Хоффманн-Ля Рош Аг | Новая фармацевтическая композиция |
| MXPA03011096A (es) * | 2001-05-29 | 2004-12-06 | Depomed Dev Ltd | Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna. |
| RU2325152C2 (ru) * | 2001-07-04 | 2008-05-27 | Сан Фармасьютикл Индастриз Лимитид | Удерживаемая в желудке система регулируемой доставки лекарственного средства |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US20050202090A1 (en) | 2002-01-03 | 2005-09-15 | Clarke Allan J. | Novel pharmaceutical dosage forms and method for producing same |
| BR0308517A (pt) * | 2002-03-18 | 2005-02-01 | Pharmacia Corp | Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar |
| GB0209481D0 (en) | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
| WO2004002445A2 (en) | 2002-06-26 | 2004-01-08 | Cadila Healthcare Limited | Novel floating dosage form |
| US20040043072A1 (en) * | 2002-09-04 | 2004-03-04 | Will Joanne Patricia | Alleviation of upper gastrointestinal irritation |
| KR20050083750A (ko) | 2002-10-11 | 2005-08-26 | 디포메드 디벨롭먼트 리미티드 | 위-체류성 레보도파 전달 형태 |
| US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| ATE428411T1 (de) * | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | Hdl-verstärkende kombinationstherapie-komplexe |
| WO2005079752A2 (en) | 2004-02-11 | 2005-09-01 | Rubicon Research Private Limited | Controlled release pharmaceutical compositions with improved bioavailability |
| CA2560927C (en) * | 2004-03-26 | 2013-05-14 | Mitsubishi Pharma Corporation | Insulin resistance-improving agent |
| FR2874325B1 (fr) | 2004-08-19 | 2006-10-20 | Sanofi Synthelabo | Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine |
| US20060073213A1 (en) | 2004-09-15 | 2006-04-06 | Hotamisligil Gokhan S | Reducing ER stress in the treatment of obesity and diabetes |
| EP1802287A2 (en) | 2004-09-27 | 2007-07-04 | Sigmoid Biotechnologies Limited | Minicapsule formulations |
| ES2540929T3 (es) * | 2005-02-01 | 2015-07-14 | Emisphere Technologies, Inc. | Sistema de administración de retención gástrica y liberación controlada |
| WO2006088305A1 (en) * | 2005-02-15 | 2006-08-24 | Chong Kun Dang Pharmaceutical Corp. | Gastric-retentive controlled release mono-matrix tablet |
| US20080194494A1 (en) * | 2005-04-26 | 2008-08-14 | Microbia, Inc. | 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia |
| US20070269512A1 (en) | 2006-05-22 | 2007-11-22 | Wang Wenhua W | Gastroretentive sustained release formulations |
| US20080103122A1 (en) | 2006-09-05 | 2008-05-01 | Schering Corporation | Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis |
| EP2124884B1 (en) | 2006-12-22 | 2019-07-10 | Ironwood Pharmaceuticals, Inc. | Compositions comprising bile acid sequestrants for treating esophageal disorders |
| WO2009158625A2 (en) | 2008-06-26 | 2009-12-30 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders |
-
2007
- 2007-12-21 EP EP07869791.9A patent/EP2124884B1/en active Active
- 2007-12-21 SI SI200732121T patent/SI2124884T1/sl unknown
- 2007-12-21 PL PL07869791T patent/PL2124884T3/pl unknown
- 2007-12-21 DK DK07869791.9T patent/DK2124884T3/da active
- 2007-12-21 WO PCT/US2007/088624 patent/WO2008080092A2/en not_active Ceased
- 2007-12-21 EP EP19185001.5A patent/EP3628307A1/en not_active Withdrawn
- 2007-12-21 JP JP2009543271A patent/JP2010514702A/ja active Pending
- 2007-12-21 LT LTEP07869791.9T patent/LT2124884T/lt unknown
- 2007-12-21 RU RU2009128202/15A patent/RU2491075C2/ru active
- 2007-12-21 EP EP12164341A patent/EP2478895A3/en not_active Withdrawn
- 2007-12-21 EP EP12164340A patent/EP2478894A3/en not_active Withdrawn
- 2007-12-21 PT PT07869791T patent/PT2124884T/pt unknown
- 2007-12-21 NZ NZ578204A patent/NZ578204A/en not_active IP Right Cessation
- 2007-12-21 HU HUE07869791A patent/HUE046465T2/hu unknown
- 2007-12-21 AU AU2007336731A patent/AU2007336731B2/en not_active Ceased
- 2007-12-21 TR TR2019/10825T patent/TR201910825T4/tr unknown
- 2007-12-21 US US12/520,748 patent/US9205094B2/en active Active
- 2007-12-21 NZ NZ598728A patent/NZ598728A/xx not_active IP Right Cessation
- 2007-12-21 ES ES07869791T patent/ES2739542T3/es active Active
- 2007-12-21 ZA ZA200904573A patent/ZA200904573B/xx unknown
- 2007-12-21 CA CA2673665A patent/CA2673665C/en active Active
-
2009
- 2009-06-21 IL IL199477A patent/IL199477A/en active IP Right Grant
-
2013
- 2013-04-17 RU RU2013117758A patent/RU2705364C2/ru active
-
2015
- 2015-01-30 JP JP2015016788A patent/JP6141891B2/ja not_active Expired - Fee Related
- 2015-11-03 US US14/931,215 patent/US20160051577A1/en not_active Abandoned
-
2016
- 2016-12-19 US US15/383,056 patent/US20170290767A1/en not_active Abandoned
-
2017
- 2017-11-15 US US15/813,850 patent/US20180235878A1/en not_active Abandoned
-
2019
- 2019-09-09 CY CY20191100940T patent/CY1122009T1/el unknown
- 2019-10-25 RU RU2019134181A patent/RU2019134181A/ru unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514702A5 (https=) | ||
| RU2013117758A (ru) | Способы и композиции для лечения расстройств пищевода | |
| AU2002316020B2 (en) | Pharmaceutical formulation comprising a proton pump inhibitor and antacids | |
| Wallace et al. | Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease | |
| CN1037932C (zh) | 能耐受胃液的口服片剂和丸剂剂型药剂的制备方法 | |
| JP2011500595A5 (https=) | ||
| JP2011520855A5 (https=) | ||
| JPH0482832A (ja) | 医薬組成物 | |
| AU2002316020A1 (en) | Pharmaceutical formulation comprising a proton pump inhibitor and antacids | |
| ES2338009T3 (es) | Composicion solida que comprende un inhibidor de la bomba de protones. | |
| CN101184482B (zh) | 抑制胃酸分泌的组合物和其制备方法 | |
| Robinson et al. | Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro‐oesophageal reflux disease | |
| CN102038648A (zh) | 治疗消化性溃疡的粉针剂及其制备方法 | |
| US9186409B2 (en) | Solid pharmaceutical composition for neutralizing stomach acid | |
| CA2605839A1 (en) | Stabilized composition of a proton pump inhibitor | |
| Lepoutre et al. | Healing of grade-II and III oesophagitis through motility stimulation with cisapride | |
| JP2011520868A (ja) | 胃酸分泌を阻害するための組成物および方法 | |
| KR20060083198A (ko) | 위산 분비의 억제를 필요로하는 병상의 치료를 위한 조성물 | |
| CN115715808B (zh) | 用于干混悬剂的干混悬颗粒及其制备方法和用途 | |
| WO2004034957A2 (en) | Methods for treatment of helicobacter pylori-associated disorders | |
| CN101513404A (zh) | 治疗消化性疾病的药物组合物及其制备方法 | |
| JP2008500365A5 (https=) | ||
| Barr et al. | Non‐steroidal anti‐inflammatory drugs and Helicobacter pylori | |
| MacLaren | A review of stress ulcer prophylaxis | |
| CN102920705A (zh) | 泰妥拉唑在制造治疗胃食管反流性疾病的药物中的应用 |